Sionna Therapeutics (NASDAQ:SION) Stock Price Up 8.8% – Here’s What Happened

Sionna Therapeutics, Inc. (NASDAQ:SION) shares traded up 8.8% on Tuesday . The stock traded as high as $39.70 and last traded at $39.8960. 76,306 shares changed hands during trading, a decline of 73% from the average session volume of 287,266 shares. The stock had previously closed at $36.66.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on SION shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Sionna Therapeutics in a research note on Monday, December 29th. Citigroup assumed coverage on Sionna Therapeutics in a report on Tuesday, February 24th. They issued an “outperform” rating for the company. Raymond James Financial reissued a “strong-buy” rating and issued a $53.00 target price on shares of Sionna Therapeutics in a report on Monday, January 5th. Guggenheim raised their target price on Sionna Therapeutics from $45.00 to $50.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Finally, BTIG Research reaffirmed a “buy” rating and set a $58.00 price target on shares of Sionna Therapeutics in a research report on Monday, March 2nd. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $50.57.

Sionna Therapeutics Trading Up 3.0%

The firm has a 50 day moving average price of $37.94 and a 200 day moving average price of $37.14. The stock has a market capitalization of $1.86 billion, a PE ratio of -21.18 and a beta of 2.98.

Sionna Therapeutics (NASDAQ:SION) last posted its quarterly earnings data on Monday, March 2nd. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.61) by $0.15.

Insider Activity

In related news, major shareholder Tpg Gp A, Llc sold 250,000 shares of the business’s stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $40.00, for a total value of $10,000,000.00. Following the transaction, the insider directly owned 6,494,962 shares of the company’s stock, valued at approximately $259,798,480. The trade was a 3.71% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Orbimed Advisors Llc sold 29,063 shares of Sionna Therapeutics stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $44.58, for a total transaction of $1,295,628.54. Following the sale, the director owned 3,530,702 shares in the company, valued at approximately $157,398,695.16. The trade was a 0.82% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 311,906 shares of company stock worth $12,759,732 in the last three months. Company insiders own 3.90% of the company’s stock.

Institutional Trading of Sionna Therapeutics

Several hedge funds have recently bought and sold shares of SION. Russell Investments Group Ltd. purchased a new position in shares of Sionna Therapeutics during the third quarter valued at about $30,000. BNP Paribas Financial Markets bought a new position in Sionna Therapeutics during the second quarter valued at approximately $31,000. GF Fund Management CO. LTD. purchased a new position in Sionna Therapeutics during the 4th quarter valued at approximately $36,000. Balyasny Asset Management L.P. bought a new stake in Sionna Therapeutics in the 4th quarter worth approximately $58,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Sionna Therapeutics during the 4th quarter worth approximately $89,000.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.